Evidence map›Paper›PMID 38323272›Full record

ArticleAmerican journal of cancer research2024

Urinary volatile organic compounds in prostate cancer biopsy pathologic risk stratification using logistic regression and multivariate analysis models.

Sabur Badmos, Elizabeth Noriega-Landa, Kiana L Holbrook, George E Quaye, Xiaogang Su, Qin Gao, Angelica A Chacon, Eric Adams, Thomas J Polascik, Adam S Feldman and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Sabur BadmosDepartment of Chemistry and Biochemistry, University of Texas at El Paso El Paso, Texas, USA.
Elizabeth Noriega-LandaDepartment of Chemistry and Biochemistry, University of Texas at El Paso El Paso, Texas, USA.
Kiana L HolbrookDepartment of Chemistry and Biochemistry, University of Texas at El Paso El Paso, Texas, USA.
George E QuayeDepartment of Mathematical Sciences, University of Texas at El Paso El Paso, Texas, USA.
Xiaogang SuDepartment of Mathematical Sciences, University of Texas at El Paso El Paso, Texas, USA.
Qin GaoDepartment of Chemistry and Biochemistry, University of Texas at El Paso El Paso, Texas, USA.
Angelica A ChaconDepartment of Chemistry and Biochemistry, University of Texas at El Paso El Paso, Texas, USA.
Eric AdamsDepartment of Urological Surgery, Duke University Medical Center Durham, North Carolina, USA.
Thomas J PolascikDepartment of Urological Surgery, Duke University Medical Center Durham, North Carolina, USA.
Adam S FeldmanDepartment of Urology, Massachusetts General Hospital Boston, Massachusetts, USA.
Michael M AnnabiInternal Medicine Clinic El Paso, Texas, USA.
Wen-Yee LeeDepartment of Chemistry and Biochemistry, University of Texas at El Paso El Paso, Texas, USA.
The University of Texas at El Paso · US

Funding

UTEP Border Biomedical Research CenterU54MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI Bibiana Marie Mancera · 2019 to 2026
$35.1M
TCCG12MD007592 · NIMHD · UNIVERSITY OF TEXAS EL PASO · PI KIRKEN, ROBERT A. · 2012 to 2018
$19.4M
G-RISE at the University of Texas at El PasoT32GM144919 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2022 to 2024
$1.5M
Urinary biomarkers for prostate cancer diagnosis and risk assessmentSC1CA245675 · NCI · UNIVERSITY OF TEXAS EL PASO · PI LEE, WEN-YEE · 2019 to 2023
$1.5M
NCI NIH HHS SC1 CA245675NIGMS NIH HHS T32 GM144919NIMHD NIH HHS G12 MD007592NIMHD NIH HHS U54 MD007592
6 · The paper itself

Abstract

Prostate cancer (PCa) is the second leading cause of cancer-related death in American men after lung cancer. The current PCa diagnostic method, the serum prostate-specific antigen (PSA) test, is not specific, thus, alternatives are needed to avoid unnecessary biopsies and over-diagnosis of clinically insignificant PCa. To explore the application of metabolomics in such effort, urine samples were collected from 386 male adults aged 44-93 years, including 247 patients with biopsy-proven PCa and 139 with biopsy-proven negative results. The PCa-positive group was further subdivided into two groups: low-grade (ISUP Grade Group = 1; n = 139) and intermediate/high-grade (ISUP Grade Group ≥ 2; n = 108). Volatile organic compounds (VOCs) in urine were extracted by stir bar sorptive extraction (SBSE) and analyzed using thermal desorption with gas chromatography and mass spectrometry (GC-MS). We used machine learning tools to develop and evaluate models for PCa diagnosis and prognosis. In total, 22,538 VOCs were identified in the urine samples. With regularized logistic regression, our model for PCa diagnosis yielded an area under the curve (AUC) of 0.99 and 0.88 for the training and testing sets respectively. Furthermore, the model for differentiating between low-grade and intermediate/high-grade PCa yielded an average AUC of 0.78 based on a repeated test-sample approach for cross-validation. These novel methods using urinary VOCs and logistic regression were developed to fill gaps in PCa screening and assessment of PCa grades prior to biopsy. Our study findings provide a promising alternative or adjunct to current PCa screening and diagnostic methods to better target patients for biopsy and mitigate the challenges associated with over-diagnosis and over-treatment of PCa.

Indexed as

chemometricsdiagnostic modelGC-MSlogistic regressionmultivariate analysisProstate cancerrisk stratificationstir-bar supportive extractionurinary biomarkersVOCs

Identifiers

PMID38323272
PMCPMC10839326
OpenAlexW4394740090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.